Pinealon Peptide with Glycine: Stack Guide | FormBlends

Trust Signals

Key Takeaways

• Pinealon is the tripeptide Glu-Asp-Arg, developed at the St. Petersburg Institute of Bioregulation; its human evidence base is thin and largely produced by the same institution that holds commercial interest in it.
• Glycine at 3 g orally before bed improved sleep efficiency in a rigorous (though small, n=11) crossover RCT by Bannai et al. (2012), making it the better-evidenced half of this stack.
• The theoretical rationale for combining the two is complementary neuroprotection via distinct pathways (proposed antioxidant gene regulation for pinealon; NMDA co-agonism and glycinergic inhibition for glycine), but no trial has tested the combination.
• Oral bioavailability of intact pinealon to the CNS has not been directly demonstrated in humans; this is the most important caveat most vendor pages omit entirely.
• Melatonin plus glycine is a head-to-head comparator with a substantially stronger evidence base for sleep and circadian outcomes.

What Is the Best Way to Use Pinealon Peptide with Glycine?

Take glycine at 3 g orally 30 to 60 minutes before bed, the dose and timing supported by Bannai et al. (2012). Pinealon, if used, is commonly cycled at 10 mg per day sublingually or orally for 10 to 30 days. Stack these at the same evening time window given both target sleep quality and neuroprotection. The combination is mechanistically plausible but not clinically validated.

Table of Contents

1. Evidence Ledger
2. Mechanism with Numbers
3. What Most Pages Get Wrong: Bioavailability
4. Why Stack These Two Specifically?
5. The Chemistry Behind the Rules of Thumb
6. Honest Head-to-Head Table
7. Dosing, Label Literacy, and COA Reading
8. Stability and Formulation Gotchas
9. Safety and Side Effects
10. FAQ
11. Sources

What Does the Evidence Actually Show?

What Is the Mechanism and Are There Specific Numbers?

Pinealon (Glu-Asp-Arg): This tripeptide was designed at the St. Petersburg Institute of Bioregulation as a "peptide bioregulator" targeting pineal and brain tissue. The proposed mechanism involves epigenetic and transcriptional effects: short peptides of this class are hypothesized to interact with DNA regulatory regions and influence gene expression, particularly genes involved in antioxidant defense (including superoxide dismutase and catalase pathways). In vitro studies from Khavinson et al. have shown reduced markers of oxidative stress in neural cell cultures exposed to pinealon. In a neonatal rat hypoxia model, pinealon administration was associated with reduced caspase-3 activity (a marker of apoptosis) compared to untreated hypoxic controls. These are model-system findings and the effect sizes and sample counts in those studies are modest. The critical gap is the absence of independent replication and human pharmacokinetic data.

Glycine: Glycine acts as an inhibitory neurotransmitter at strychnine-sensitive glycine receptors (GlyR, primarily in spinal cord and brainstem) and as a co-agonist at NMDA receptors in the CNS, where it binds the GluN1 subunit glycine-binding site. The co-agonist role means glycine can modulate glutamatergic tone without fully activating the receptor. Bannai et al. (2012) showed that oral glycine 3 g reduced rectal temperature (a proxy for sleep-onset-associated core body cooling) and improved polysomnographic sleep efficiency and self-reported fatigue in a crossover study of 11 healthy volunteers. The temperature effect is attributed to peripheral vasodilation via NMDA receptor activity in the hypothalamic preoptic area. Glycine is also a major precursor to glutathione (the tripeptide gamma-Glu-Cys-Gly), so chronic glycine loading has theoretical relevance to antioxidant status, though the dose required to meaningfully raise glutathione in healthy adults is debated.

What Most Pages Get Wrong: The Oral Bioavailability Problem

Why Stack Pinealon Specifically with Glycine?

The stack rationale, as articulated in the bioregulator community, rests on three overlapping ideas:

1. Complementary antioxidant pathways. Pinealon's proposed antioxidant activity operates at the gene-regulation level (upregulating endogenous antioxidant enzyme expression). Glycine provides substrate for glutathione synthesis and has direct radical-scavenging properties in vitro. These are non-redundant pathways if both work as proposed.
2. NMDA modulation. Glycine's NMDA co-agonism may modulate excitotoxicity, which is also a concern in the neuroprotection context where pinealon is typically deployed. Using glycine alongside a neuroprotective peptide to address the glutamate-excess component of neural injury is mechanistically coherent.
3. Evening timing alignment. Pinealon targets pineal tissue and is often used for circadian or sleep-quality applications. Glycine's sleep-onset facilitation (via core temperature reduction) makes an evening dose of both pragmatically consistent without requiring separate timing windows.

None of this has been tested as a combination in a controlled trial. This is a mechanistic rationale stack, not an evidence-based combination therapy.

Why Do the Storage and Separation Rules Exist?

Why store pinealon frozen when lyophilized? Lyophilization (freeze-drying) removes water to reduce hydrolytic degradation of peptide bonds. At room temperature and even at 4 degrees Celsius, residual moisture and thermal energy accelerate peptide bond hydrolysis, converting the tripeptide progressively into free amino acids. Minus 20 degrees Celsius substantially slows this reaction by reducing the kinetic energy available for bond cleavage and by limiting residual water mobility. Once reconstituted in aqueous solution, the same hydrolysis risk returns. The acidic residues in pinealon (Glu, Asp) make the Asp-Arg bond somewhat susceptible to acid-catalyzed hydrolysis, which is relevant if reconstitution buffer pH is not controlled.

Why does glycine not have the same storage concern? Glycine is a single amino acid, not a peptide. There is no amide bond to hydrolyze. It is stable as a solid at room temperature for years if kept dry. The storage concerns for this stack are entirely about the pinealon component.

Why avoid reconstituting pinealon in bacteriostatic water containing benzyl alcohol if using sublingually? Benzyl alcohol at the concentrations used in bacteriostatic water (typically 0.9%) is generally safe for injection but is an irritant to oral mucosa and should not be swallowed in any volume. If sublingual use is intended, reconstitution in sterile water for injection is appropriate. This is a formulation gotcha that vendors frequently fail to specify.

How Does This Stack Compare to Alternatives?

Honest verdict: Melatonin plus glycine wins on every evidence metric. The only reason to consider the pinealon plus glycine stack is if you are specifically interested in the bioregulator hypothesis and accept the uncertainty premium. Pinealon adds cost and regulatory risk without adding certainty.

How Do You Dose This Stack and Read a COA?

Glycine dosing: 3 g orally, dissolved in water, 30 to 60 minutes before sleep. This is the dose from Bannai et al. (2012). There is no strong evidence that higher doses (some protocols suggest up to 5 g) produce proportionally greater benefit. Glycine powder is cheap and COA verification is simple: confirm identity by HPLC or NMR, purity above 99%, and absence of heavy metals above USP limits.

Pinealon dosing: The bioregulator literature uses 10 mg per day in oral or sublingual form, cycled over 10 to 30 days. Some protocols describe two to three cycles per year. There is no dose-finding RCT. The 10 mg figure comes from the original St. Petersburg protocols, not from a dose-escalation study.

Reading a pinealon COA:

• Confirm sequence: Glu-Asp-Arg, sometimes written as H-Glu-Asp-Arg-OH or using single-letter code EDR.
• Purity by HPLC: look for greater than 98% purity. Values below 95% suggest significant impurities that may include truncated sequences or aggregates.
• Molecular weight confirmation: the expected MW for Glu-Asp-Arg is approximately 418 Da. Mass spectrometry (ESI-MS or MALDI) should confirm this within instrument tolerance.
• Endotoxin testing: any injectable-route research compound should have an LAL (limulus amebocyte lysate) endotoxin result below 1 EU/mg.
• Water content: Karl Fischer titration should show residual water below 6% for a lyophilized peptide.

Reconstitution math: If you have 10 mg of lyophilized pinealon and want a 1 mg/mL working solution, add 10 mL of sterile water for injection. For sublingual dosing at 10 mg/day, that is 1 mL of this solution under the tongue and held for 60 to 90 seconds. Label the vial with reconstitution date and store at 2 to 8 degrees Celsius.

Stability and Formulation Gotchas

What degraded pinealon looks like: A properly lyophilized batch is a white to off-white powder that reconstitutes to a clear, colorless solution. Yellowing of the powder before reconstitution, cloudiness or particulate matter in the reconstituted solution, or a noticeably acidic or unusual odor are all indicators of degradation or contamination. Do not use a batch with any of these signs.

Freeze-thaw cycling: Each freeze-thaw cycle creates mechanical stress on the peptide matrix and promotes aggregation. Best practice is to reconstitute only the volume you will use within two to four weeks, and aliquot the rest as lyophilized powder rather than refreezing solution repeatedly.

Glycine is stable: Glycine powder requires only dry, cool storage away from strong acids or oxidizers. It does not need refrigeration. Glycine in aqueous solution is stable at refrigerator temperatures for weeks. There is no practical formulation concern here.

What Are the Safety and Side Effect Considerations?

Glycine at 3 g is well-tolerated in healthy adults across multiple studies. Mild gastrointestinal effects (loose stools, bloating) are reported by a minority of users at higher doses. Glycine is contraindicated in individuals with certain organic acidemias (very rare).

Pinealon's human safety profile has not been characterized in an independent, adequately powered trial. The institutional studies report no significant adverse events, but this claim carries low weight given the source. Because pinealon acts on neural tissue via (proposed) gene-regulatory mechanisms, the theoretical concern about long-term effects on gene expression exists, though it is speculative. Pregnant or breastfeeding individuals, and those with active neurological conditions or on anticonvulsants, should not use pinealon outside formal research settings.

No published drug interaction data exist for pinealon plus glycine or for pinealon plus any pharmaceutical.

FAQ

What is pinealon and what does it do?

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation. It is classified as a peptide bioregulator targeting brain and pineal gland tissue. Animal and limited human data suggest neuroprotective and antioxidant effects, but no large-scale human RCTs exist.

Why stack pinealon with glycine?

Glycine is an inhibitory neurotransmitter and precursor to glutathione. When stacked with pinealon, the rationale is complementary neuroprotection: pinealon's proposed antioxidant gene-regulatory activity plus glycine's NMDA receptor co-agonism and glycine receptor (GlyR) inhibitory signaling. This is mechanistic rationale only; no human trial has tested this specific combination.

What dose of glycine is used alongside pinealon?

Studies on glycine's sleep and cognitive effects commonly use 3 g orally at night (Bannai et al., 2012). No published protocol specifies a co-dose with pinealon. Common pinealon protocols in the bioregulator literature use 10 mg per day orally or sublingually for cycles of 10 to 30 days.

Is there human RCT evidence for pinealon?

No large-scale independent human RCT for pinealon exists in the PubMed-indexed literature as of 2026. Most data come from in vitro studies, rodent models, and small clinical observations from the St. Petersburg Institute group, which creates significant risk of institutional bias.

Does glycine improve sleep quality on its own?

Yes, with moderate evidence. A 2012 randomized crossover trial by Bannai et al. (n=11) found 3 g oral glycine before bed significantly reduced fatigue and improved sleep efficiency scores. The sample size is small but the design is rigorous for this research area.

Can pinealon and glycine be taken together in the same dose?

There is no known chemical incompatibility between pinealon (Glu-Asp-Arg) and glycine in solution. However, glycine at gram doses is taken orally while pinealon is often used sublingually or as an injectable research compound. The routes and timing do not require them to be co-formulated.

What does pinealon degrade to and how should it be stored?

Pinealon is a small tripeptide susceptible to hydrolysis once reconstituted in aqueous solution. Lyophilized powder is stable at minus 20 degrees Celsius for extended periods. Reconstituted solution should be refrigerated at 2 to 8 degrees Celsius and used within 2 to 4 weeks. Repeated freeze-thaw cycles accelerate degradation.

How does this stack compare to melatonin plus glycine?

Melatonin plus glycine has a substantially stronger evidence base for sleep quality than pinealon plus glycine. Melatonin has multiple human RCTs, an established pharmacokinetic profile, and regulatory approval in many countries. Pinealon's advantage is a proposed broader neuroprotective mechanism, but that claim rests on much weaker evidence.

Are there side effects or safety concerns with this stack?

Glycine at 3 g is generally well-tolerated in healthy adults. Pinealon's safety profile in humans is not well characterized beyond small institutional studies. No published interaction data exist for the combination. Anyone using pinealon outside a supervised research context assumes risk from an incompletely characterized compound.

Does oral pinealon actually reach the brain?

This is the key bioavailability question most pages skip. As a tripeptide, pinealon is subject to gastrointestinal proteolysis. Some di- and tripeptides survive absorption intact via PepT1 transporters, but blood-brain barrier penetration of intact Glu-Asp-Arg has not been directly demonstrated in humans. The bioregulator literature claims CNS activity but does not provide direct pharmacokinetic proof.

Is pinealon legal to buy and use?

Pinealon is not FDA-approved as a drug or dietary supplement ingredient in the United States. It exists in a regulatory gray zone as a research compound. It is not on the WADA prohibited list as of 2026. Laws vary by country. Purchasers should verify local regulations before acquiring it.

Sources

1. Bannai M, Kawai N, Ono K, Nakahara K, Murakami N. The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Front Neurol. 2012;3:61. PMID 22529837.
2. Khavinson VKh, Linkova NS, Kvetnoy IM, et al. Peptide bioregulators: a review. Adv Gerontol. Various years. St. Petersburg Institute of Bioregulation and Gerontology publications (institutional series).
3. Daniel H. Molecular and integrative physiology of intestinal peptide transport. Annu Rev Physiol. 2004;66:361-384. PMID 14977407. (PepT1 transporter mechanism.)
4. Hertz L, Zielke HR. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci. 2004;27(12):735-743. PMID 15541514. (Glycine and NMDA receptor co-agonism context.)
5. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 1987;325(6104):529-531. PMID 2433595. (Original NMDA co-agonist demonstration.)
6. Meister A, Anderson ME. Glutathione. Annu Rev Biochem. 1983;52:711-760. PMID 6137189. (Glycine as glutathione precursor.)
7. FDA. Title 21 CFR Parts 310 and 312. Drug definitions and research compound regulations. (Regulatory framework reference.)
8. WADA. 2026 Prohibited List. World Anti-Doping Agency. (Pinealon not listed as of current edition.)

Related peptide guides

• Peptide therapy guide hub
• Peptide dosage and reconstitution calculator
• BPC 157 with TB 500: The Wolverine Stack Explained | FormBlends
• Best Anti Aging Peptides Injections: Ranked by Evidence | FormBlends
• Best Peptide for Recovery (2026): Evidence-Ranked Guide | FormBlends
• Best Peptide Stack for Muscle Growth and Fat Loss | FormBlends
• Best Peptides for Men Over 40 | FormBlends